Hypothermic Oxygenated Perfusion Improves Extended Criteria Donor Liver Graft Function and Reduces Duration of Hospitalization Without Extra Cost: The PERPHO Study

Michel Rayar, Jean-Marie Beaurepaire, Emma Bajeux, Stéphanie Hamonic, Thomas Renard, Clara Locher, Véronique Desfourneaux, Aude Merdrignac, Damien Bergeat, Mohamed Lakehal, Laurent Sulpice, Pauline Houssel-Debry, Caroline Jezequel, Christophe Camus, Edouard Bardou-Jacquet, Bernard Meunier, Michel Rayar, Jean-Marie Beaurepaire, Emma Bajeux, Stéphanie Hamonic, Thomas Renard, Clara Locher, Véronique Desfourneaux, Aude Merdrignac, Damien Bergeat, Mohamed Lakehal, Laurent Sulpice, Pauline Houssel-Debry, Caroline Jezequel, Christophe Camus, Edouard Bardou-Jacquet, Bernard Meunier

Abstract

Few studies have evaluated the efficacy or the cost of hypothermic oxygenated perfusion (HOPE) in the conservation of extended criteria donor (ECD) grafts from donation after brain death (DBD) donors during liver transplantation (LT). We performed a prospective, monocentric study (NCT03376074) designed to evaluate the interest of HOPE for ECD-DBD grafts. For comparison, a control group was selected after propensity score matching among patients who received transplants between 2010 and 2017. Between February and November 2018, the HOPE procedure was used in 25 LTs. Immediately after LT, the median aspartate aminotransferase (AST) level was significantly lower in the HOPE group (724UI versus 1284UI; P = 0.046) as were the alanine aminotransferase (ALT; 392UI versus 720UI; P = 0.01), lactate (2.2 versus 2.7; P = 0.01) There was a significant reduction in intensive care unit stay (3 versus 5 days; P = 0.01) and hospitalization (15 versus 20 days; P = 0.01). The incidence of early allograft dysfunction (EAD; 28% versus 42%; P = 0.22) was similar . A level of AST or ALT in perfusate >800UI was found to be highly predictive of EAD occurrence (areas under the curve, 0.92 and 0.91, respectively). The 12-month graft (88% versus 89.5%; P = 1.00) and patient survival rates (91% versus 91.3%; P = 1.00) were similar. The additional cost of HOPE was estimated at € 5298 per patient. The difference between costs and revenues, from the hospital's perspective, was not different between the HOPE and control groups (respectively, € 3023 versus € 4059]; IC, -€ 5470 and € 8652). HOPE may improve ECD graft function and reduce hospitalization stay without extra cost. These results must be confirmed in a randomized trial.

Copyright © 2020 by the American Association for the Study of Liver Diseases.

References

    1. l’Agence de la biomédecine. Rapport annuel médical et scientifique 2018. . Published September 25, 2019. Accessed October 13, 2019.
    1. Noack K, Bronk SF, Kato A, Gores GJ. The greater vulnerability of bile duct cells to reoxygenation injury than to anoxia: implications for the pathogenesis of biliary strictures after liver transplantation. Transplantation 1993;56:495-500.
    1. Nemes B, Gámán G, Polak WG, Gelley F, Hara T, Ono S. Extended-criteria donors in liver transplantation part II: reviewing the impact of extended-criteria donors on the complications and outcomes of liver transplantation. Expert Rev Gastroenterol Hepatol 2016;10:841-859.
    1. Durand F, Renz JF, Alkofer B, Burra P, Clavien P-A, Porte RJ, et al. Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transpl 2008;14:1694-1707.
    1. Eren EA, Latchana N, Beal E, Hayes D Jr, Whitson B, Black SM. Donations after circulatory death in liver transplant. Exp Clin Transplant 2016;14:463-470.
    1. Foley DP, Fernandez LA, Leverson G, Anderson M, Mezrich J, Sollinger HW, et al. Biliary complications after liver transplantation from donation after cardiac death donors: an analysis of risk factors and long term outcomes from a single center. Ann Surg 2011;253:817-825.
    1. Dutkowski P, Polak WG, Muiesan P, Schlegel A, Verhoeven CJ, Scalera I, et al. First comparison of Hypothermic Oxygenated PErfusion versus static cold storage of human donation after cardiac death liver transplants: an international-matched case analysis. Ann Surg 2015;262:764-770; discussion 770-771.
    1. Rayar M, Levi Sandri GB, Cusumano C, Locher C, Houssel-Debry P, Camus C, et al. Benefits of temporary portocaval shunt during orthotopic liver transplantation with vena cava preservation: a propensity score analysis. Liver Transpl 2017;23:174-183.
    1. Karangwa SA, Dutkowski P, Fontes P, Friend PJ, Guarrera JV, Markmann JF, et al. Machine perfusion of donor livers for transplantation: a proposal for standardized nomenclature and reporting guidelines. Am J Transplant 2016;16:2932-2942.
    1. Olthoff KM, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl 2010;16:943-949.
    1. Paugam-Burtz C, Kavafyan J, Merckx P, Dahmani S, Sommacale D, Ramsay M, et al. Postreperfusion syndrome during liver transplantation for cirrhosis: outcome and predictors. Liver Transpl 2009;15:522-529.
    1. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF III, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612.
    1. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012;120:c179-c184.
    1. APCext: Effect of temporary porto-caval shunt during liver transplantation on function of liver graft from extended criteria donor. identifier: NCT02784199. Published May 26, 2016. . Accessed January 15, 2020.
    1. Guarrera JV, Henry SD, Samstein B, Odeh-Ramadan R, Minkhabwala M, Goldstein MJ, et al. Hypothermic machine preservation in human liver transplantation: the first clinical series. Am J Transplant 2010;10:372-381.
    1. Dutkowski P, Schlegel A, de Oliveira M, Müllhaupt B, Neff F, Clavien P-A, et al. HOPE for human liver grafts obtained from donors after cardiac death. J Hepatol 2014;60:765-772.
    1. Otao R, Beppu T, Isiko T, Mima K, Okabe H, Hayashi H, et al. External biliary drainage and liver regeneration after major hepatectomy. Br J Surg 2012;99:1569-1574.
    1. Guarrera JV, Henry SD, Samstein B, Reznik E, Musat C, Lukose TI, et al. Hypothermic machine preservation facilitates successful transplantation of “orphan” extended criteria donor livers. Am J Transplant 2015;15:161-169.
    1. Schlegel A, de Rougemont O, Graf R, Clavien P-A, Philipp D. Protective mechanisms of end-ischemic cold machine perfusion in DCD liver grafts. J Hepatol 2013;58:278-286.
    1. Schlegel A, Dutkowski P. Role of hypothermic machine perfusion in liver transplantation. Transplant Int 2015;28:677-689.
    1. Lüer B, Koetting M, Efferz P, Minor T. Role of oxygen during hypothermic machine perfusion preservation of the liver. Transplant Int 2010;23:944-950.
    1. van Rijn R, Karimian N, Matton APM, Burlage LC, Westerkamp AC, van den Berg AP, et al. Dual hypothermic oxygenated machine perfusion in liver transplants donated after circulatory death: dual hypothermic oxygenated machine perfusion in liver transplantation. Br J Surg 2017;104:907-917.
    1. Nasralla D, Coussios CC, Mergental H, Akhtar MZ, Butler AJ, Ceresa CDL, et al. A randomized trial of normothermic preservation in liver transplantation. Nature 2018;557:50-56.
    1. Patrono D, Surra A, Catalano G, Rizza G, Berchialla P, Martini S, et al. Hypothermic oxygenated machine perfusion of liver grafts from brain-dead donors. Sci Rep 2019;9:9337.
    1. Hypothermic Oxygenated Perfusion for extended criteria donors in liver transplantation (HOPExt). identifier: NCT03929523. . Published April 29, 2019. Accessed January 15, 2020.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe